Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease. Transl. Neurodegener. 2, 19.Teo, K.C.; Ho, S.L. Monoamine oxidase-B (MAO-B) inhibitors: Implications for disease-modification in Parkinson's disease. Transl. Neurodegener. 2013, 2, 19...
(redirected fromMonoamine oxidase inhibitors) Thesaurus Medical Encyclopedia monoamine oxidase inhibitor n.Abbr.MAOI Any of a class of antidepressant drugs that block the action of monoamine oxidase in the brain, thereby allowing the accumulation of monoamine neurotransmitters such as norepinephrine and sero...
Monoamine Oxidase Inhibitors The enzymemonoamine oxidase(MAO) occurs in humans in two forms, MAO-A and MAO-B. In neurons, MAO-A catabolizesnorepinephrineand serotonin by deamination; both MAO-A and MAO-B destroy intraneuronal dopamine andtyramine. A class of drug calledmonoamine oxidase inhib...
The aim of this article is to synthesize informations about monoamine oxidase inhibitors drugs (MAOI) used in the treatment of depression. General informations on monoamine oxidase (MAO) and its kinetic properties are presented. MAO is an enzyme that degrades catecholamines and their 3-methoxy deriv...
The animal pharmacology of the monoamine oxidase inhibitors (MAOIs*) has been reviewed previously by Zirkle and Kaiser (1964), Biel et al. (1964), Pscheidt (1964), Horita (1967), and Jacob and Simon (1968).
1. The principal routes of metabolism of the following monoamine oxidase inhibitors (MAOIs) are described: phenelzine, tranylcypromine, pargyline, deprenyl, moclobemide, and brofaromine. 2. Acetylation of phenelzine appears to be a minor metabolic pathway. Phenelzine is a substrate as well as an...
Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis Background: Monoamine oxidase inhibitors (MAOIs) were the first class of modern antidepressants; however, they are under-utilized as compared to the newer ... R Suchting,...
Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studiesParkinson's diseasePiperineMonoamine oxidaseStructure-activity-toxicity relationshipP-gpBBB Blood-brain barrier...
The development of monoamine oxidase (MAO) inhibitors has followed a winding path. At the origin was the finding of E. A. Zeller that iproniazid, a hydrazine derivative designed to improve the tuberculostatic action of isoniazid, caused potent inhibition
1. Despite the fact that monoamine oxidase inhibitors have been used clinically and in animal experiments for many years, much still remains unknown about their metabolism. An overview of the metabolic aspects of several monoamine oxidase inhibitors, including phenelzine, tranylcypromine, pheniprazine, ...